Novo Nordisk's Market Math: A Raised Forecast, a Bruised Share Price, and a Pivot to Oral Obesity Care
Published on 08/06/2026 at 12:41 | Redaktion boerse-global.de
There is a peculiar arithmetic playing out at Novo Nordisk right now. The Danish drugmaker has told investors that 2026 will be less painful than feared, yet the share price keeps sliding. On the latest trading day alone, the stock dropped as much as 7.1 percent in Copenhagen, according to Reuters and The Business Times, before closing the week at 38.72 euros — a 13.37 percent decline over seven days. The company had just delivered its second-quarter numbers, and the market's verdict was unambiguous: meeting expectations is no longer enough.
The stock now trades roughly 30 percent below its 52-week high of 54.86 euros, though it has clawed back some ground, with a 3.80 percent bounce in a single session and a current price around 40.19 euros. That puts the shares about 32.84 percent above their 52-week low of 30.25 euros and almost exactly at the 200-day moving average of 40.30 euros — a technical level that suggests stabilization rather than a continued freefall.
The Numbers Tell Two Different Stories
On the surface, the second-quarter report looks respectable. Adjusted revenue rose 7 percent to 78.488 billion Danish kroner, while adjusted operating profit climbed 11 percent. Management also narrowed its full-year guidance, now expecting adjusted growth of between 0 and minus 6 percent, a meaningful improvement from the earlier range of minus 4 to minus 12 percent.
But strip out the adjustments, and the picture darkens considerably. Reported operating profit fell 16 percent, weighed down by 6.3 billion kroner in non-cash impairments — including 4.0 billion kroner tied to the pipeline candidate Monlunabant. The message buried beneath the upgraded guidance is that Novo Nordisk is writing down assets while simultaneously selling operational progress.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Adding to the pressure, the Phase 3 ZEUS trial for Ziltivekimab in cardiovascular disease missed its primary endpoint. For a company trying to position itself beyond weight loss alone, that is not a footnote.
A Competitive Landscape That Has Shifted
The clinical setbacks come at a time when the competitive dynamics in injectable GLP-1 therapies have turned decisively against Novo Nordisk. Eli Lilly reported a 48 percent revenue surge, driven by Mounjaro's nearly $10 billion quarterly sales. In the U.S. injectable GLP-1 market, Lilly now commands a 60.9 percent share, leaving Novo Nordisk with 38.8 percent. That shift explains a good portion of the stock's 8.72 percent decline since the start of the year.
The oral segment, however, tells a different story — and it is here that Novo Nordisk's defenders find their strongest argument. The Wegovy tablet generated 3.2 billion kroner (roughly $494 million) in second-quarter sales, narrowly missing the analyst consensus of 3.27 billion kroner but dwarfing Lilly's oral competitor Foundayo, which managed just $98 million in the same period. Since its U.S. launch in January, more than five million prescriptions for the Wegovy pill have been written, giving Novo Nordisk control of roughly 90 percent of the oral obesity market.
Following European Commission approval in July, the tablet has now launched in its first EU market, along with rollouts in the United Arab Emirates and the United Kingdom. That near-monopoly in oral therapies serves as a buffer against the pricing pressure affecting the broader industry.
The Restructuring Beneath the Surface
The cost-cutting program announced in September 2025 continues to cast a long shadow. Novo Nordisk is eliminating 11 percent of its workforce globally — around 9,000 positions, including 5,000 in Denmark — as part of an effort to reduce expenses and, in the company's own phrasing, "rejuvenate" growth. Reports have cited a figure of 15 percent job cuts, with some observers describing a cultural shift toward "commercial pragmatism" under the leadership of Maziar Mike Doustdar, who took over as CEO and sought to reassure investors this week with promises of faster research and pipeline rebuilding.
The fact that a restructuring announced nearly a year ago remains a topic of debate underscores how deeply the company is grappling with structural challenges that no single quarter can resolve. The share buyback program continues — just over 27 million B-shares repurchased for 7.53 billion kroner as of early August, within a program sized at 15 billion kroner — but these are stability signals, not growth narratives.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Political Risk in the Background
Germany's government signaled early this week that it wants to reconsider the reimbursement status of "lifestyle medications" such as Ozempic and Wegovy. Should that translate into policy changes, it would hit Novo Nordisk in an already vulnerable market segment.
Analysts at AlphaValue/Baader have described the company's revised guidance as "excessively cautious," suggesting room for further upgrades if the production expansion in Kalundborg proceeds as planned. Jefferies, meanwhile, pointed to "many open questions for 2027" regarding long-term competitiveness in the obesity market.
The market's reaction to the quarterly report — ignoring good news because of eroded trust in management — may be the most telling signal of all. Novo Nordisk is no longer the unassailable leader it once was; it is a leaner, more commercially aggressive company defending a valuable niche in oral metabolic medicine. That is a different story than a year ago, but not necessarily a weaker one. Until the Capital Markets Day on September 21, the share price is likely to remain a reflection of that uncertainty, with recovery and substantive questions sitting closer together than the upgraded guidance suggests.
Ad
Novo Nordisk Stock: New Analysis - 6 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
